DALLAS – – September 08, 2026 -- A2035 Ventures has added Preston Dunlap, the first Chief Technology Officer and Chief Architect of the U.S. Space Force and U.S. Air Force, and Sean Perry, formerly with Agentic AI at Meta Superintelligence Labs, to the technical leadership of Project 777, its compounding intelligence architecture, as the company pursues strategic discussions with major AI organizations.
Space Force's first CTO has advised Project 777 since April 2025
Dunlap now serves as Technical Advisor, having provided technical perspective on the architecture and its evidence base for roughly a year and a half before the leadership expansion was announced.
Former Meta Superintelligence Labs lead joins as Strategic Technical Lead
Perry reviewed Project 777's Technical Proof Packet after departing Meta's superintelligence organization and is now helping lead technical diligence and strategic technical engagement for the company.
Project 777 claims three demonstrated breakthroughs: runtime safety, bounded self-improvement, cross-domain operation
According to A2035 Ventures Founder and Architect TK Stohlman, the system independently governs which agent outputs may advance, allows validated improvements to persist and compound over time, and runs the same core architecture across materially different sectors without redesign. Built-in layers continuously check agent reasoning, evidence, and safety, and can halt or redirect work before it advances, preventing the system from approving its own output.
Company links its approach to Google DeepMind's pathways toward artificial superintelligence
A2035 Ventures says Project 777 has been built and operated over the past two years around a governed architecture combining bounded recursive self-improvement, a model-agnostic multi-agent intelligence layer, and independent runtime control -- dynamics Google DeepMind's "From AGI to ASI" paper identifies as credible pathways toward superintelligence. The system retains validated intelligence, evaluation history, accepted and rejected changes, and accumulated operating experience even as underlying frontier models are swapped out.
Atherion Bioresearch deal values up to three disease programs at over $1 million in non-royalty consideration
A2035 Ventures previously signed an option and license agreement with Atherion Bioresearch covering up to three disease programs generated by Project 777. Aggregate potential non-royalty consideration across the programs can exceed $1 million, with additional downstream royalties tied to commercialization.
A2035 Ventures is advancing strategic discussions with major technology and frontier-AI organizations while selectively licensing Project 777-generated solutions.